Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Medicines Co. Stops 2 Anti-Clotting Drug Trials

By Pharmaceutical Processing | May 13, 2009

PARSIPPANY, N.J. (AP) — Medicines Co. said Wednesday it stopped late-stage testing of cangrelor, an anti-clotting drug candidate, because it was not meeting its goals in two clinical trials. Medicines Co. has been conducting late-stage studies for more than three years, testing cangrelor’s ability to prevent blood clots in patients who have had angioplasties to clear blocked arteries. An independent monitoring committee said cangrelor did not appear to be more effective than Plavix, an older drug, and did not appear equally effective or more effective than standard treatments alone. Medicines Co. shares plunged on the news, losing almost half their value in premarket trading. The stock fell to $5.95 — which would represent a seven-year low — after closing at $11.14 Tuesday. The monitoring committee recommended that Medicines Co. stop enrolling patients in both trials and examine all the data. It said the drug might be more effective when used for a shorter time when oral drugs can’t be used. The company said it plans to step up testing of cangrelor in that setting. The monitoring committee said a trial called Champion-Platform trial would not meet its goal. The trial was intended to compare a combination of cangrelor and standard treatment to standard treatment alone, and Medicines Co. hoped it would show cangrelor was as effective or better than those drugs at preventing clotting. The committee also said cangrelor was not significantly more effective than Plavix in a study called Champion-PCI. Plavix, or clopidogrel, is sold by Sanofi-Aventis of France, and is one of the world’s top drugs by revenue. Medicines Co. said it plans to enroll 200 patients in a study called Bridge, which is intended to show the drug significantly reduces the buildup of platelets over five days. The trial will involve patients who stop taking clopidogrel as they prepare for heart surgery. It planned to enroll more than 15,000 patients in the two late-stage studies.

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards